{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:29:25Z","timestamp":1780320565758,"version":"3.54.1"},"reference-count":37,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet Med"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>A cost\u2010effectiveness analysis was conducted to compare insulin glargine 300\u2009U\/mL (Gla\u2010300) versus insulin degludec 100\u2009U\/mL (IDeg\u2010100) in insulin\u2010na\u00efve adults with type 2 diabetes (T2D) sub\u2010optimally controlled with oral anti\u2010diabetic drugs (OADs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The BRAVO diabetes model was used to assess costs and outcomes for once\u2010daily Gla\u2010300 versus once\u2010daily IDeg\u2010100 from a US healthcare sector perspective. Baseline clinical data were based on BRIGHT, a 24\u2010week, non\u2010inferiority, randomised control trial comparing Gla\u2010300 and IDeg\u2010100 in adults with T2D sub\u2010optimally controlled with OADs (with or without glucagon\u2010like peptide\u20101 receptor agonists). Treatment costs were based on doses observed in BRIGHT as well as net prices. Costs associated with complications were based on published literature. Lifetime costs (US$) and quality\u2010adjusted life\u2010years (QALYs) were predicted and used to calculate incremental cost\u2010effectiveness ratio estimates; extensive scenario and sensitivity analyses were conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall lifetime medical costs were estimated to be $327,904 and $330,154 for people receiving Gla\u2010300 and IDeg\u2010100, respectively; insulin costs were $43,477 and $44,367, respectively. People receiving Gla\u2010300 gained 8.024 QALYs and 18.55 life\u2010years, while people receiving IDeg\u2010100 gained 7.997 QALYs and 18.52 life\u2010years. Because Gla\u2010300 was associated with a cost\u2010saving of $2250 and 0.027 additional QALYs, it was considered to be dominant compared with IDeg\u2010100. Results of the scenario and sensitivity analyses confirmed the robustness of the base case results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Gla\u2010300 was the dominant treatment option compared with IDeg\u2010100 based on the willingness\u2010to\u2010pay threshold of $50,000\/QALY. Results remained robust against a wide range of alternative assumptions on key parameters.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dme.15112","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T09:49:52Z","timestamp":1681120192000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost\u2010effectiveness analysis of once\u2010daily insulin glargine 300\u2009U\/mL versus insulin degludec 100\u2009U\/mL using the BRAVO diabetes model"],"prefix":"10.1111","volume":"40","author":[{"given":"Hui","family":"Shao","sequence":"first","affiliation":[{"name":"Hubert Department of Global Health Emory Rollins School of Public Health  Atlanta Georgia USA"},{"name":"Department of Pharmaceutical Outcomes and Policy University of Florida College of Pharmacy  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizheng","family":"Shi","sequence":"additional","affiliation":[{"name":"School of Public Health and Tropical Medicine Tulane University  New Orleans Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Fonseca","sequence":"additional","affiliation":[{"name":"School of Medicine Tulane University  New Orleans Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Jabbar Omar","family":"Alsaleh","sequence":"additional","affiliation":[{"name":"Sanofi  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder","family":"Gill","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Sanofi  Reading UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Centers for Disease Control and Prevention.Type 2 diabetes. Accessed January 25 2023.https:\/\/www.cdc.gov\/diabetes\/basics\/type2.html.2022"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0787-8"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0007"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.3.385"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0939"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3329"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0559"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108316"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.12.2856"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2010.06.003"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.19.2542"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0465"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.08.007"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0227"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7705"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0662-1"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00775-8"},{"key":"e_1_2_9_20_1","unstructured":"Institute for Clinical and Economic Review.Unsupported price increase report \u2013 2020 assessment. Accessed November 26 2021.https:\/\/icer.org\/wp\u2010content\/uploads\/2020\/11\/ICER_UPI_2020_Report_011221.pdf"},{"key":"e_1_2_9_21_1","unstructured":"Agency for Healthcare Research and Quality.Medical expenditure panel survey. Accessed August 3 2022.https:\/\/www.meps.ahrq.gov\/mepsweb.2022"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.4843"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0381"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2538"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2151"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13793"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-022-01925-9"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13616"},{"issue":"1","key":"e_1_2_9_29_1","article-title":"Cost\u2010effectiveness of insulin glargine 300 units\/ml (GLA\u2010300) vs insulin degludec 100 units\/ml (IDEG) IN T2D","volume":"66","author":"Murphy D","year":"2017","journal-title":"Diabetes"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0236-9"},{"key":"e_1_2_9_31_1","unstructured":"Institute for Clinical and Economic Review.Tirzepatide for type 2 diabetes 2021. Accessed October 14 2021.https:\/\/icer.org\/wp\u2010content\/uploads\/2021\/06\/ICER_Type\u20102\u2010Diabetes_Draft\u2010Scope_063021.pdf"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.12.2238"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1257978"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2048"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2082"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2012.05.002"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.87"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1178126"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.15112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T05:00:58Z","timestamp":1692421258000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.15112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/dme.15112"],"URL":"https:\/\/doi.org\/10.1111\/dme.15112","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"2022-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15112"}}